HRS-5965

Unknown / undisclosed

Phase 3complete

Evidence outlook · registrational

Paroxysmal Nocturnal Hemoglobinuria: registrational trials complete

Its supporting mid-stage studies have completed. Its registrational studies have completed. Check News and the registry record for topline outcomes.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Paroxysmal Nocturnal Hemoglobinuria
NCT06715943 · Chengdu Suncadia Medicine Co., Ltd.
2025-01-07 – 2026-01-06 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT06593938 · Chengdu Suncadia Medicine Co., Ltd.
2024-10-25 – 2025-07-31 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
Other / comorbidity
NCT07014826 · Chengdu Suncadia Medicine Co., Ltd.
2025-06-04 – 2028-12 · Primary IgA Nephropathy
What this study did
Phase 2 (4)
Paroxysmal Nocturnal Hemoglobinuria
NCT06238544 · Chengdu Suncadia Medicine Co., Ltd.
2024-02-06 – 2027-12 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT06051357 · Chengdu Suncadia Medicine Co., Ltd.
2023-11-15 – 2024-03-25 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
Other / comorbidity
NCT07582133 · Chengdu Suncadia Medicine Co., Ltd.
2026-07-06 – 2029-11 · Primary IgA Nephropathy
What this study did
NCT06137768 · Chengdu Suncadia Medicine Co., Ltd.
2023-12-19 – 2025-10-17 · Primary IgA Nephropathy
What this study did
Phase 1 (7)
Paroxysmal Nocturnal Hemoglobinuria
NCT07035665 · Chengdu Suncadia Medicine Co., Ltd.
2025-06-30 – 2025-07-22 · IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT06490991 · Chengdu Suncadia Medicine Co., Ltd.
2024-07-17 – 2024-09-10 · Paroxysmal Nocturnal Hemoglobinuria,IgA Nephropathy
What this study did
Other / comorbidity
NCT06674915 · Chengdu Suncadia Medicine Co., Ltd.
2024-11-26 – 2026-01-16 · Complement Mediated Primary or Secondary Glomerular Diseases
What this study did
NCT07040787 · Chengdu Suncadia Medicine Co., Ltd.
2025-07-08 – 2025-08-17 · Complement Mediated Glomerular Diseases, Hemolytic Anemia
What this study did
NCT06684041 · Chengdu Suncadia Medicine Co., Ltd.
2024-11-09 – 2025-04-07 · Hemolytic Anemia
What this study did
NCT06567392 · Chengdu Suncadia Medicine Co., Ltd.
2024-09-03 – 2024-10-08 · Complement Mediated Primary or Secondary Glomerular Diseases
What this study did
NCT05505955 · Chengdu Suncadia Medicine Co., Ltd.
2022-10-08 – 2023-11-03 · Glomerulonephritis
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for Paroxysmal Nocturnal Hemoglobinuria: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
HRS-5965: this drugPhase 3UndisclosedComplement Factor Bnot yet gradedNo reviewed efficacy summary in this indication
Eculizumab (Soliris)ApprovedMonoclonal antibodyComplement C5Weak signalFeatured results are safety only in this race
Iptacopan (Fabhalta)ApprovedSmall moleculeComplement Factor BPartial signal
NCT04558918: At 24 weeks, without transfusion: Hb increase of 2 g/dL or more in 51 of 60 on iptacopan vs 0 of 35 on anti-C5; Hb of 12 g/dL or more in 42 of 60 vs 0 of 35. Superiority shown on both primaries.
NCT04820530: Single arm, 24 weeks: estimated 92.2% (95% CI 82.5 to 100.0) of 40 complement-inhibitor-naive patients had a sustained Hb increase of 2 g/dL or more without transfusion. No comparator.
Pegcetacoplan (Empaveli)ApprovedPeptideComplement C3Partial signal
NCT03500549: Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP (Baseline and Week 16): Pegcetacoplan to Pegcetacoplan 2.37 Grams per deciliter (g/dL) (Standard Error 0.363) | Eculizumab to Pegcetacoplan -1.47 Grams per deciliter (g/dL) (Standard Error 0.666)
Ravulizumab (Ultomiris)ApprovedMonoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
Pozelimab (Veopoz)Phase 3Monoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
FWY003
Phase 2(overall)
UndisclosedComplement Factor B
not yet graded(overall)
No reviewed efficacy summary in this indication
ZaltenibartPhase 2Monoclonal antibodyMASP-3Weak signal
NCT05972967: Interim (data cut-off 8 July 2024): primary endpoints were safety and tolerability; zaltenibart was well tolerated, treatment-related adverse events in 46.2% of patients (mostly mild to moderate), 1 discontinuation for a treatment-emergent serious adverse event. Hemoglobin rose from a mean baseline of 9.26 g/dL by 3.39 g/dL at day 29 and 3.27 g/dL at day 169 on add-on to ravulizumab (N=13), and by 3.85 g/dL at day 309 on monotherapy (N=6, P=0.003).
ALN-CFBPhase 1/2RNA / oligonucleotideComplement Factor Bnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow HRS-5965 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
October 2027 (1)
Phase 3Primary IgA NephropathyActive not recruiting
Est. primary completion 2027-10 · NCT07014826 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Paroxysmal Nocturnal HemoglobinuriaActive not recruiting
Est. primary completion 2027-12 · NCT06238544 · CT.gov ↗
What to watch
2029 (1)
July 2029 (1)
Phase 2Primary IgA NephropathyRecruiting
Est. primary completion 2029-07 · NCT07582133 · CT.gov ↗
What to watch

See the full readout calendar ↗